Treatment of the neuroblastoma-associated opsoclonus-myoclonus-ataxia (OMA) syndrome with high-dose methylprednisolone
Corresponding Author
Suna Emir MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Suna Emir is fellow in Pediatric Oncology, Canan Akyüz, Professor of Pediatrics, and Münevver Büyükpamukçu, Professor of Pediatrics.
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.Search for more papers by this authorCanan Akyüz MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorMünevver Büyükpamukçu MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorCorresponding Author
Suna Emir MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Suna Emir is fellow in Pediatric Oncology, Canan Akyüz, Professor of Pediatrics, and Münevver Büyükpamukçu, Professor of Pediatrics.
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.Search for more papers by this authorCanan Akyüz MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorMünevver Büyükpamukçu MD
Department of Pediatric Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this author
REFERENCES
- 1 Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-Myoclonus-Ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies—a report from the Children's Cancer group study. Med Pediatr Oncol 2001; 36: 612–622.
- 2 Pranzatelli MR. The Neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1992; 15: 186–228.
- 3 Scully RE, Mark EJ, MC Neely BU. Case records of the Massachusetts General Hospital Weekly clinicopathological exercises. N Eng J Med 1995; 333: 579–586.
- 4 Pranzatelli MR. The immunopharmacology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol 1996; 19: 1–47.
- 5 Fisher PG, Wechsler DS, Singer HS. Anti-Hu antibody in a neuroblastoma associated paraneoplastic syndrome. Pediatr Neurol 1994; 10: 309–312.
- 6
Janss A,
Sladky J,
Chatten J, et al.
Opsoclonus/myoclonus: paraneoplastic syndrome of neuroblastoma.
Med Pediatr Oncol
1996;
26:
272–279.
10.1002/(SICI)1096-911X(199604)26:4<272::AID-MPO11>3.0.CO;2-H CAS PubMed Web of Science® Google Scholar
- 7 Russo C, Cohn SL, Petruzzi MJ, et al. Long-term neurologic outcome in children with Opsoclonus-myoclonus associated with neuroblastoma: a report from the pediatric oncology group. Med Pediatr Oncol 1997; 29: 284–288.
- 8 Koh PS, Raffensperger JG, Berry S. et al. Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. J Pediatr 1994; 125: 712–716.
- 9
Veneselli E,
Conte M,
Biancheri R, et al.
Effect of steroid and high-dose immunoglobulin therapy on opsoclonus-myoclonus syndrome occurring in neuroblastoma.
Med Pediatr Oncol
1998;
30:
15–17.
10.1002/(SICI)1096-911X(199801)30:1<15::AID-MPO6>3.0.CO;2-3 CAS PubMed Web of Science® Google Scholar
- 10 Petruzzi MJ, Alarcon PA. Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. J Pediatr 1995; 127: 328–329.
- 11 Özsoylu Ş. High-dose intravenous methylprednisolone (HIVMP) in hematological disorders. Hematol Rev 1990; 4: 197–207.
